Animal Study Results for the 'ALT-M5' Candidate Presented at ObesityWeek

Alteogen, a bio platform company, said on November 16 that it presented animal study results for candidates in its ALT-M5 series of ultra-long-acting obesity treatments at ObesityWeek 2026, the annual scientific meeting of the Obesity Society, held in Washington, D.C.


Alteogen is developing an ultra-long-acting platform that builds on its existing technology for selectively attaching drugs to specific sites on proteins. The platform enables multiple active ingredients to be attached and extends the duration of a drug's effects.


A view of Alteogen's headquarters and research institute in Yuseong-gu, Daejeon. Alteogen

A view of Alteogen's headquarters and research institute in Yuseong-gu, Daejeon. Alteogen

View original image

Its first pipeline candidate, ALT-M5, is an obesity treatment designed for once-monthly administration. It uses a platform for which an international patent application under the Patent Cooperation Treaty (PCT) was completed in September 2026. In this study, researchers used a substance made by attaching a peptide and a fatty acid to specific sites on an incretin-based fusion protein to assess its persistence in the body, weight-loss effects, and weight changes after treatment discontinuation in animal models.


In a pharmacokinetic (PK) assessment, the half-life of ALT-M5B4, an ALT-M5 candidate, was 68.1 hours in laboratory animals. This was more than four times longer than that of retatrutide, Eli Lilly's triple-agonist obesity treatment candidate. Alteogen said the findings confirmed the potential to develop a once-monthly formulation.


In a pharmacodynamic (PD) assessment involving diet-induced obese (DIO) mice, twice-weekly administration of ALT-M5B418 resulted in a 55.3% reduction in body weight from baseline on day 21. The weight reduction rates were 49.0% in the retatrutide group and 21.0% in the tirzepatide group.


Weight regain after treatment discontinuation was also lower than in the control group. Two weeks after the end of treatment, the weight regain rate for ALT-M5B418 was 34.7%, below the 44.2% recorded in the retatrutide group.


Alteogen plans to use the study to confirm the treatment's weight-loss effects and potential to maintain weight after treatment discontinuation, and to accelerate development of an ultra-long-acting obesity treatment administered once a month.



“In a study using retatrutide as the comparator drug, which has shown the greatest weight-loss effects among obesity treatments reported to date, we confirmed superior results in weight loss, suppression of weight regain after treatment discontinuation, and persistence in the body,” said Jeon Tae-yeon, CEO of Alteogen. “Following Hybrozyme, we will broaden the applications of our new ultra-long-acting platform and develop an obesity treatment that offers greater dosing convenience and better weight maintenance.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing